Loss to follow-up and mortality among HIV-infected people co-infected with TB at ART initiation in Durban, South Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 1, 2012, Pages 25-30

  Bassett, Ingrid V ^a   Chetty, Senica ^b   Wang, Bingxia ^a,c   Mazibuko, Matilda ^b   Giddy, Janet ^b   Lu, Zhigang ^a   Walensky, Rochelle P ^a,c,d   Freedberg, Kenneth A ^a,c,d   Losina, Elena ^a,c,d,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MCCORD HOSPITAL   (South Africa)

^c HARVARD UNIVERSITY   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

HIV; long term outcomes; mortality; South Africa; tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; BACTERIUM CULTURE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVENTION STUDY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; PRIORITY JOURNAL; SOUTH AFRICA; SPUTUM CULTURE;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; LOST TO FOLLOW-UP; MALE; PATIENT COMPLIANCE; SOUTH AFRICA; TUBERCULOSIS;

EID: 83655167188     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31823d3aba     Document Type: Article

References (21)

1. World Health Organization. Global tuberculosis control: a short update to the 2009 report. Available at: http://www.who.int/tb/publications/global- report/2009/update/tbu-9.pdf. Accessed February 17, 2011.
2. Lawn SD, Myer L, Bekker LG, et al. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006;20:1605-1612. (Pubitemid 44162402)
3. Lawn SD, Myer L, Orrell C, et al. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS. 2005;19:2141-2148. (Pubitemid 41669003)
4. Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS. 2007;21:713-719. (Pubitemid 46568628)
5. World Health Organization. The WHO three 'I's meeting: report of a joint WHO HIV/AIDS and TB department meeting, 2008. Available at: http://www.who.int/ hiv/pub/meetingreports/WHO-3Is-meeting-report.pdf. Accessed February 17, 2011.
6. Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis. 2010;51:823-829.
7. Lawn SD, Kranzer K, Edwards DJ, et al. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS. 2010;24:1323-1328.
8. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006; 296:782-793. (Pubitemid 44223102)
9. Westreich D, MacPhail P, Van Rie A, et al. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS. 2009;23:707-715.
10. Lawn SD, Edwards DJ, Kranzer K, et al. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS. 2009;23: 1875-1880.
11. Shah S, Demissie M, Lambert L, et al. Intensified tuberculosis case finding among HIV-Infected persons from a voluntary counseling and testing center in Addis Ababa, Ethiopia. J Acquir Immune Defic Syndr. 2009;50:537-545.
12. Ojikutu BO, Zheng H, Walensky RP, et al. Predictors of mortality in patients initiating antiretroviral therapy in Durban, South Africa. S Afr Med J. 2008;98:204-208. (Pubitemid 351516347)
13. Bassett IV, Wang B, Chetty S, et al. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr. 2009;51:135-139.
14. South African Government Information Sector. Operational plan for comprehensive HIV and AIDS care, management and treatment for South Africa, 2003. Available at: http://www.info.gov.za/issues/hiv/careplan. htm. Accessed February 17, 2011.
15. Republic of South Africa Department of Health. The South African national tuberculosis control programme practical guidelines, 2004. Available at: http://www.kznhealth.gov.za/chrp/documents/Guidelines/-Guidelines%20National/ Tuberculosis/SA%20TB%20Guidelines% 202004.pdf. Accessed January 17, 2011.
16. Hermans SM, Kiragga AN, Schaefer P, et al. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. PLoS ONE. 2010;5:e10527.
17. Brinkhof MWG, Spycher BD, Yiannoutsos C, et al. Adjusting Mortality for loss to follow-up: analysis of 5ive ART programmes in Sub-Saharan Africa. PLoS ONE. 2010;5:e14149.
18. Geng EH, Emenyonu N, Bwana MD, et al. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA. 2008;300:506-507.
19. L'Homme RF, Nijland HM, Gras L, et al. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. AIDS. 2009;23: 863-865.
20. McIlleron H, Meintjes G, Burman WJ, et al. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis. 2007;196 (suppl 1):S63-S75. (Pubitemid 47206086)
21. World Health Organization. Interim policy on collaborative HIV/TB activities. Available at: http://whqlibdoc.who.int/hq/2004/who-htm-tb-2004. 330.pdf. Accessed September 29, 2011.